热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE anti-human CD19 Antibody
产品名称：
PE anti-human CD19 Antibody
产品类别：
抗体
产品编号：
302254
产品应用：
302254
[价格]
规格 价格 库存
100µg ￥ 1022 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
?g size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The CD19 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the ?g size, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections8 and blocking of B cell proliferation. Clone HIB19 is not recommended for formalin-fixed paraffin-embedded sections. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 302267 & 302268).

?

Clone HIB19 partially blocks anti-human CD19 clones 4G7 and SJ25C1 staining based on in-house testing

Application References

(PubMed link indicates BioLegend citation)
  1. Schlossman S, et al. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  3. Bradbury L, et al. 1993. J. Immunol. 151:2915.
  4. Joseph A, et al. 2010. J. Virol. 84:6645. PubMed
  5. Wang X, et al. 2010. Haematologica. 95:884. (FC) PubMed
  6. Walker JD, et al. 2009. J. Immunol. 182:1548. (Block) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Hansen A, et al. 2002. Arthritis Rheum. 46:2160. (IHC)
  9. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  10. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Basnett J, et al. 2017. PLoS One. . 10.1371/journal.pone.0188042. PubMed
  2. Chabi S, et al. 2020. Cell Reports. 29(8):2307-2320.e6.. PubMed
  3. Sipe CJ, et al. 2022. Int J Mol Sci. 23:. PubMed
  4. Merah-Mourah F, et al. 2021. Curr Protoc. 1:e229. PubMed
  5. SoRelle ED, et al. 2022. Front Immunol. 13:1001145. PubMed
  6. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  7. Ye Y, et al. 2022. Nat Commun. 13:6458. PubMed
  8. Malik-Chaudhry HK, et al. 2021. MAbs. 13:1890411. PubMed
  9. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  10. Serra–Peinado C, et al. 2019. Nat Commun. 10:3705. PubMed
  11. Huang Y, et al. 2020. Cancer Cell. 36(6):630-644.e9.. PubMed
  12. Matsui K, et al. 2015. PLoS One. 10: 0137195. PubMed
  13. Richardson SE, et al. 2021. STAR Protocols. 2(2):100420. PubMed
  14. SoRelle ED, et al. 2022. Cell Rep. 40:111286. PubMed
  15. Mondala PK, et al. 2021. Cell Stem Cell. 28(4):623-636.e9. PubMed
  16. Frame JM, et al. 2020. Developmental Cell. 55(2):133-149.e6. PubMed
  17. Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed
  18. Vereertbrugghen A, et al. 2021. Front Oncol. 11:598319. PubMed
  19. Xiao X, et al. 2019. Cell Discov. 5:2. PubMed
  20. Abdul-Jawad S, et al. 2021. Cancer Cell. 39(2):257-275.e6. PubMed
  21. Laing AG, et al. 2020. Nat Med. 26:1623. PubMed
  22. McComb S, et al. 2016. Sci Transl Med. 8: 339ra70. PubMed
  23. White C, et al. 2014. J Immunol. 193:5933. PubMed
  24. Kim ST, et al. 2022. Nat Commun. 13:1970. PubMed
  25. Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed
  26. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  27. Cho A, et al. 2019. Cell Rep. 28:909. PubMed
  28. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  29. Zirbes A, et al. 2021. J Mammary Gland Biol Neoplasia. 26:247. PubMed
  30. Moquin-Beaudry G, et al. 2022. Cell Rep Methods. 2:100153. PubMed
  31. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
  32. B?iers C, et al. 2018. Dev Cell. 44:362. PubMed
  33. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  34. Japp AS, et al. 2021. Cell. 184(3):827-839.e14. PubMed
  35. Lu P, et al. 2021. Blood Cancer J. 11:39. PubMed
  36. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  37. Kreye J, et al. 2020. Cell. 183(4):1058-1069.e19. PubMed
  38. Shen J, et al. 2021. Sci Adv. 7:eabi9787. PubMed
  39. Jing Y, et al. 2021. Signal Transduct Target Ther. 6:345. PubMed
  40. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
  41. Luong-Gardiol N, et al. 2019. Cancer Cell. 35:649. PubMed
  42. Velázquez–Avila M, et al. 2019. Leukemia. 33:1337. PubMed
  43. Palazzo A, et al. 2018. J Immunol. 200:2304. PubMed
  44. Kreye J, et al. 2020. bioRxiv. . PubMed
  45. Bigler M, et al. 2015. PLoS One. 10: 0145635. PubMed
  46. Wang X, et al. 2021. Front Endocrinol (Lausanne). 12:666195. PubMed
  47. Sureshchandra S, et al. 2021. iScience. 24:102690. PubMed
  48. Yamanaka M, et al. 2009. Glycobiology. 1.375694444. PubMed
  49. Caeser R, et al. 2021. Nat Protoc. 16:2499. PubMed
  50. Roider T, et al. 2021. Blood Adv. 5:5060. PubMed
  51. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  52. Gu X, et al. 2022. Vaccines (Basel). 10:. PubMed
  53. Greiner V, et al. 2019. iScience. 0.75625. PubMed
  54. Zumaquero E, et al. 2019. Elife. 8. PubMed
  55. Wang L, et al. 2021. Microbiol Spectr. 9:e0124621. PubMed
  56. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  57. Joly P, et al. 2017. PLoS One. 12(6):e0180568. PubMed
  58. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  59. Khosravi-Maharlooei M, et al. 2021. J Autoimmun. 119:102612. PubMed
  60. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  61. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  62. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  63. de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed
  64. Turner JS, et al. 2020. Nature. 586:127. PubMed
  65. Zhang Q, et al. 2021. Bone Joint Res. 10:226. PubMed
  66. Sanchez HN, et al. 2020. Nat Commun. 0.5. PubMed
  67. Li W, et al. 2020. Immunity. 53(2):456-470. PubMed
  68. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  69. Han AR, et al. 2021. Int J Stem Cells. 14:203. PubMed
  70. Avsec D, et al. 2022. Cell Death Dis. 13:860. PubMed
  71. Jiang Q et al. 2019. Cancer cell. 35(1):81-94 . PubMed
  72. Fisher JG, et al. 2021. Front Oncol. 11:785635. PubMed
  73. Gomes AM, et al. 2018. Cell Rep. 25:2821. PubMed
  74. Theurich S et al. 2017. Cell metabolism. 26(1):171-184 . PubMed
  75. Lavaert M, et al. 2020. Immunity. 52(6):1088-1104. PubMed
  76. Collison J, et al. 2015. J Immunol. 195: 1162-1170. PubMed
  77. Kim ST, et al. 2021. J Immunother Cancer. 9:. PubMed
  78. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  79. Ruan Y, et al. 2022. Exp Ther Med. 23:47. PubMed
  80. Zheng L, et al. 2020. Clin Cancer Res. 26:3694. PubMed
  81. Turner JS, et al. 2021. Nature. 595:421. PubMed
  82. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  83. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  84. Vora AA, et al. 2021. STAR Protocols. 2(2):100565. PubMed
RRID
AB_314237 (BioLegend Cat. No. 302207) AB_314238 (BioLegend Cat. No. 302208) AB_2564142 (BioLegend Cat. No. 302254)

Antigen Details

Structure
Ig superfamily, type I transmembrane glycoprotein, 95 kD
Distribution

B lineage (except plasma cells), follicular dendritic cells

Function
B cell activation and differentiation
Ligand/Receptor
Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Tedder T, et al. 1994. Immunol. Today 15:437.
2. Bradbury L, et al. 1993. J. Immunol. 151:2915.

Gene ID
930 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线